Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where S. Arunmozhi Balajee is active.

Publication


Featured researches published by S. Arunmozhi Balajee.


The Journal of Infectious Diseases | 2004

Detection of galactomannan antigenemia by enzyme immunoassay for the diagnosis of invasive aspergillosis: Variables that affect performance

Kieren A. Marr; S. Arunmozhi Balajee; Lisa McLaughlin; Marc Tabouret; Christopher Bentsen; Thomas J. Walsh

Invasive aspergillosis (IA) is a frequent complication of blood or marrow transplantation. Previous studies have reported that the Aspergillus galactomannan enzyme immunoassay (GM EIA) may be a useful diagnostic tool for IA, but its sensitivity is variable. We examined the performance of the GM EIA in 986 serum samples from 67 patients. Results demonstrated that decreasing the index cutoff for positivity to 0.5 increased its sensitivity, with minimal loss of specificity. The low cutoff increased the duration of test positivity before diagnosis by clinical means. Sensitivity was highest in patients who did not receive preventative mold-active antifungals (87.5%). A rabbit model demonstrated that the level of circulating antigen correlated with the tissue fungus burden. A quantifiable response to antifungal therapy in clinical samples and the rabbit model supports the development of this assay for early diagnosis and therapeutic monitoring. The 0.5 cutoff may allow for better performance as an early diagnostic test.


Clinical Infectious Diseases | 2004

Breakthrough Fungal Infections in Stem Cell Transplant Recipients Receiving Voriconazole

Alexander Imhof; S. Arunmozhi Balajee; David N. Fredricks; Janet A. Englund; Kieren A. Marr

Infection with voriconazole-resistant fungi may become problematic, because organisms with decreased susceptibility have been noted. Breakthrough fungal infections occurred in 13 of 139 patients who received voriconazole at our center during the period of September 1998 through September 2003. Zygomycetes were found in 6 patients, and Candida glabrata bloodstream infection occurred in 4 patients. Minimal inhibitory concentrations were > or =1 microg/mL for all available isolates. Yeasts and molds with decreased susceptibility to voriconazole may cause invasive infection in patients treated successfully for aspergillosis.


Eukaryotic Cell | 2005

Aspergillus lentulus sp. nov., a New Sibling Species of A. fumigatus

S. Arunmozhi Balajee; Jennifer L. Gribskov; Edward N Hanley; David C. Nickle; Kieren A. Marr

ABSTRACT In a prior study, we identified seven clinical isolates of an Aspergillus sp. that were slow to sporulate in multiple media and demonstrated decreased in vitro susceptibilities to multiple antifungals, including amphotericin B, itraconazole, voriconazole, and caspofungin. These isolates were initially considered to be variants of Aspergillus fumigatus because of differences in mitochondrial cytochrome b sequences and unique randomly amplified polymorphic DNA PCR patterns (S. A. Balajee, M. Weaver, A. Imhof, J. Gribskov, and K. A. Marr, Antimicrob. Agents Chemother. 48: 1197-1203, 2004). The present study was performed to clarify the taxonomic status of these organisms by phylogenetic analyses based on multilocus sequence typing of five genes (the β-tubulin gene, the rodlet A gene, the salt-responsive gene, the mitochondrial cytochrome b gene, and the internal transcribed spacer regions). Results revealed that four of the seven variant isolates clustered together in a clade very distant from A. fumigatus and distinct from other members of the A. fumigatus group. This new clade, consisting of four members, was monophyletic with strong bootstrap support when the protein-encoding regions were analyzed, indicating a new species status under the phylogenetic species concept. Phenotype studies revealed that the variant isolate has smaller conidial heads with diminutive vesicles compared to A. fumigatus and is not able to survive at 48°C. Our findings suggest the presence of a previously unrecognized, potentially drug-resistant Aspergillus species that we designate A. lentulus.


Journal of Clinical Microbiology | 2004

Aspergillus Galactomannan Enzyme Immunoassay and Quantitative PCR for Diagnosis of Invasive Aspergillosis with Bronchoalveolar Lavage Fluid

Benjamin Musher; David N. Fredricks; Wendy Leisenring; S. Arunmozhi Balajee; Caitlin A. Smith; Kieren A. Marr

ABSTRACT Invasive pulmonary aspergillosis (IPA) is frequent and often fatal in hematopoietic stem cell transplant patients. Diagnosis requires microbiological or histopathologic demonstration of the organism in tissues; however, cultivation of Aspergillus species from respiratory secretions has low diagnostic sensitivity. Assays to detect Aspergillus antigen or DNA in bronchoalveolar lavage (BAL) fluid could facilitate earlier diagnosis, thereby guiding optimal therapy and obviating the need for additional costly and potentially morbid diagnostic evaluation. We evaluated the performance of a galactomannan enzyme immunoassay (GM EIA; Bio-Rad) by using a range of index cutoffs to define positivity and a quantitative PCR (qPCR) assay for the detection of Aspergillus species from BAL samples of patients with proven and probable IPA (case patients; n = 49) and without IPA (control patients; n = 50). The sensitivity of the GM EIA was 61% with an index cutoff of 1.0 and 76% with an index cutoff of 0.5; the corresponding specificities were 98 and 94%, respectively. The sensitivity and specificity of qPCR assay were 67 and 100%, respectively. The sensitivity with 22 culture-negative BAL specimens from patients with IPA was 41% for GM EIA with an index cutoff of 1.0, 59% for GM EIA with an index cutoff of 0.5, and 36% for qPCR assay. GM EIA indices and DNA quantities corresponded to BAL fungal burdens, with culture-positive samples having larger amounts of antigen and DNA compared to culture-negative samples. GM EIA and qPCR assay add to the sensitivity of BAL for diagnosing IPA in high-risk patients, with excellent specificity. Adjunctive use of these tests may reduce dependence on invasive diagnostic procedures.


Eukaryotic Cell | 2005

LaeA, a Regulator of Morphogenetic Fungal Virulence Factors

Jin Woo Bok; S. Arunmozhi Balajee; Kieren A. Marr; David R. Andes; Kristian Fog Nielsen; Jens Christian Frisvad; Nancy P. Keller

ABSTRACT Opportunistic animal and plant pathogens, well represented by the genus Aspergillus, have evolved unique mechanisms to adapt to and avoid host defenses. Aspergillus fumigatus, an increasingly serious pathogen owing to expanding numbers of immunocompromised patients, causes the majority of human infections; however, an inability to identify bona fide virulence factors has impeded therapeutic advances. We show that an A. fumigatus mutation in a developmentally expressed transcriptional regulator (ΔlaeA) coordinating morphological and chemical differentiation reduces virulence in a murine model; impaired virulence is associated with decreased levels of pulmonary gliotoxin and multiple changes in conidial and hyphal susceptibility to host phagocytes ex vivo. LaeA, a conserved protein in filamentous fungi, is a developmental regulator of virulence genes and, possibly, the first antimicrobial target specific to filamentous fungi that are pathogenic to plants and animals.


Journal of Clinical Microbiology | 2010

Internet-Accessible DNA Sequence Database for Identifying Fusaria from Human and Animal Infections

Kerry O'Donnell; Deanna A. Sutton; Michael G. Rinaldi; Brice A. J. Sarver; S. Arunmozhi Balajee; Hans Josef Schroers; Richard C. Summerbell; Vincent Robert; Pedro W. Crous; Ning Zhang; Takayuki Aoki; Kyongyong Jung; Jongsun Park; Yong-Hwan Lee; Seogchan Kang; Bongsoo Park; David M. Geiser

ABSTRACT Because less than one-third of clinically relevant fusaria can be accurately identified to species level using phenotypic data (i.e., morphological species recognition), we constructed a three-locus DNA sequence database to facilitate molecular identification of the 69 Fusarium species associated with human or animal mycoses encountered in clinical microbiology laboratories. The database comprises partial sequences from three nuclear genes: translation elongation factor 1α (EF-1α), the largest subunit of RNA polymerase (RPB1), and the second largest subunit of RNA polymerase (RPB2). These three gene fragments can be amplified by PCR and sequenced using primers that are conserved across the phylogenetic breadth of Fusarium. Phylogenetic analyses of the combined data set reveal that, with the exception of two monotypic lineages, all clinically relevant fusaria are nested in one of eight variously sized and strongly supported species complexes. The monophyletic lineages have been named informally to facilitate communication of an isolates clade membership and genetic diversity. To identify isolates to the species included within the database, partial DNA sequence data from one or more of the three genes can be used as a BLAST query against the database which is Web accessible at FUSARIUM-ID (http://isolate.fusariumdb.org ) and the Centraalbureau voor Schimmelcultures (CBS-KNAW) Fungal Biodiversity Center (http://www.cbs.knaw.nl/fusarium ). Alternatively, isolates can be identified via phylogenetic analysis by adding sequences of unknowns to the DNA sequence alignment, which can be downloaded from the two aforementioned websites. The utility of this database should increase significantly as members of the clinical microbiology community deposit in internationally accessible culture collections (e.g., CBS-KNAW or the Fusarium Research Center) cultures of novel mycosis-associated fusaria, along with associated, corrected sequence chromatograms and data, so that the sequence results can be verified and isolates are made available for future study.


Eukaryotic Cell | 2006

Molecular Studies Reveal Frequent Misidentification of Aspergillus fumigatus by Morphotyping

S. Arunmozhi Balajee; David C. Nickle; János Varga; Kieren A. Marr

ABSTRACT Aspergillus fumigatus has been understood to be the most common cause of invasive aspergillosis (IA) in all epidemiological surveys. However, recent studies have uncovered a large degree of genetic heterogeneity between isolates morphologically identified as A. fumigatus, leading to the description of a new species, Aspergillus lentulus. Here, we examined the genetic diversity of clinical isolates identified as A. fumigatus using restriction enzyme polymorphism analysis and sequence-based identification. Analysis of 50 clinical isolates from geographically diverse locations recorded the presence of at least three distinct species: A. lentulus, Aspergillus udagawae, and A. fumigatus. In vitro, A. lentulus isolates demonstrated decreased susceptibility to antifungal drugs currently used for IA, including amphotericin B, voriconazole, and caspofungin; A. udagawae isolates demonstrated decreased in vitro susceptibility to amphotericin B. Results of the present study demonstrate that current phenotypic methods to identify fungi do not differentiate between genetically distinct species in the A. fumigatus group. Differential antifungal susceptibilities of these species may account for some of the reported poor outcomes of therapy in clinical studies.


Journal of Clinical Microbiology | 2009

Molecular Identification of Aspergillus Species Collected for the Transplant-Associated Infection Surveillance Network

S. Arunmozhi Balajee; Rui Kano; John W. Baddley; Stephen A. Moser; Kieren A. Marr; Barbara D. Alexander; David R. Andes; Dimitrios P. Kontoyiannis; Giancarlo Perrone; Stephen W. Peterson; Mary E. Brandt; Peter G. Pappas; Tom Chiller

ABSTRACT A large aggregate collection of clinical isolates of aspergilli (n = 218) from transplant patients with proven or probable invasive aspergillosis was available from the Transplant-Associated Infection Surveillance Network, a 6-year prospective surveillance study. To determine the Aspergillus species distribution in this collection, isolates were subjected to comparative sequence analyses by use of the internal transcribed spacer and β-tubulin regions. Aspergillus fumigatus was the predominant species recovered, followed by A. flavus and A. niger. Several newly described species were identified, including A. lentulus and A. calidoustus; both species had high in vitro MICs to multiple antifungal drugs. Aspergillus tubingensis, a member of the A. niger species complex, is described from clinical specimens; all A. tubingensis isolates had low in vitro MICs to antifungal drugs.


Antimicrobial Agents and Chemotherapy | 2011

Azole Resistance in Aspergillus fumigatus Isolates from the ARTEMIS Global Surveillance Study Is Primarily Due to the TR/L98H Mutation in the cyp51A Gene

Shawn R. Lockhart; João P. Frade; Kizee A. Etienne; Michael A. Pfaller; Daniel J. Diekema; S. Arunmozhi Balajee

ABSTRACT We surveyed 497 isolates of Aspergillus fumigatus collected from 2008 to 2009 as part of the ARTEMIS global surveillance study for elevated MIC values to itraconazole, voriconazole, and posaconazole. Sequencing of the cyp51A gene revealed that 8/29 isolates with elevated MIC values to one or more triazoles, all originating in China, contained the TR/L98H mutation associated with resistant European isolates of A. fumigatus. This is the first time the TR/L98H mutation has been identified outside Europe.


Clinical Infectious Diseases | 2011

Evaluation of a Newly Developed Lateral Flow Immunoassay for the Diagnosis of Cryptococcosis

Mark D. Lindsley; Nanthawan Mekha; Henry C. Baggett; Yupha Surinthong; Rinrapas Autthateinchai; Pongpun Sawatwong; Julie R. Harris; Benjamin J. Park; Tom Chiller; S. Arunmozhi Balajee; Natteewan Poonwan

This study, evaluating the performance of a novel cryptococcal lateral flow immunoassay, shows that the assay performs as well as available diagnostic methods is economical, rapid, and easy to perform; and as such can be a point of care test in resource limited settings.

Collaboration


Dive into the S. Arunmozhi Balajee's collaboration.

Top Co-Authors

Avatar

Kieren A. Marr

Johns Hopkins University

View shared research outputs
Top Co-Authors

Avatar

Mary E. Brandt

Centers for Disease Control and Prevention

View shared research outputs
Top Co-Authors

Avatar

Kizee A. Etienne

Centers for Disease Control and Prevention

View shared research outputs
Top Co-Authors

Avatar

Tom Chiller

Centers for Disease Control and Prevention

View shared research outputs
Top Co-Authors

Avatar

Lalitha Gade

Centers for Disease Control and Prevention

View shared research outputs
Top Co-Authors

Avatar

Jacques Boncy

Public health laboratory

View shared research outputs
Top Co-Authors

Avatar

David R. Andes

University of Wisconsin-Madison

View shared research outputs
Top Co-Authors

Avatar

Eszter Deak

Centers for Disease Control and Prevention

View shared research outputs
Top Co-Authors

Avatar

Jennifer L. Gribskov

Fred Hutchinson Cancer Research Center

View shared research outputs
Top Co-Authors

Avatar

Julie R. Harris

Centers for Disease Control and Prevention

View shared research outputs
Researchain Logo
Decentralizing Knowledge